KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
Latest Information Update: 01 Feb 2025
Price :
$35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Sacituzumab Tirumotecan (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms KEYMAKER-U01 Substudy 01E
- Sponsors Merck Sharp & Dohme
- 01 Feb 2025 New trial record